Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one‐year, randomized, clinical trial in …
GW Cannon, JR Caldwell, P Holt… - … : Official Journal of …, 2000 - Wiley Online Library
GW Cannon, JR Caldwell, P Holt, B McLean, B Seidenberg, J Bolognese, E Ehrich…
Arthritis & Rheumatism: Official Journal of the American College …, 2000•Wiley Online LibraryObjective To compare the clinical efficacy of rofecoxib, a specific inhibitor of cyclooxygenase
2 (COX‐2), with that of diclofenac in patients with osteoarthritis (OA) and to evaluate the
safety and tolerability of rofecoxib. Methods We performed a randomized, double‐blind,
active comparator–controlled trial in 784 adults with OA of the knee or hip. Patients were
randomized to 1 of 3 treatment groups: 12.5 mg of rofecoxib once daily, 25 mg of rofecoxib
once daily, and 50 mg of diclofenac 3 times daily. Clinical efficacy and safety were evaluated …
2 (COX‐2), with that of diclofenac in patients with osteoarthritis (OA) and to evaluate the
safety and tolerability of rofecoxib. Methods We performed a randomized, double‐blind,
active comparator–controlled trial in 784 adults with OA of the knee or hip. Patients were
randomized to 1 of 3 treatment groups: 12.5 mg of rofecoxib once daily, 25 mg of rofecoxib
once daily, and 50 mg of diclofenac 3 times daily. Clinical efficacy and safety were evaluated …
Objective
To compare the clinical efficacy of rofecoxib, a specific inhibitor of cyclooxygenase 2 (COX‐2), with that of diclofenac in patients with osteoarthritis (OA) and to evaluate the safety and tolerability of rofecoxib.
Methods
We performed a randomized, double‐blind, active comparator–controlled trial in 784 adults with OA of the knee or hip. Patients were randomized to 1 of 3 treatment groups: 12.5 mg of rofecoxib once daily, 25 mg of rofecoxib once daily, and 50 mg of diclofenac 3 times daily. Clinical efficacy and safety were evaluated over a 1‐year continuous treatment period.
Results
Rofecoxib at dosages of 12.5 and 25 mg demonstrated efficacy that was clinically comparable to that of diclofenac, as assessed by all 3 primary end points according to predefined comparability criteria. Results from secondary end points were consistent with those of the primary end points. There were small statistical differences favoring diclofenac for 2 of the end points. All treatments were well tolerated.
Conclusion
Rofecoxib was well tolerated and provided efficacy that was clinically comparable, according to predefined statistical criteria, to that of 150 mg of diclofenac per day in this 1‐year study. Specific inhibition of COX‐2 provided therapeutic efficacy in OA.
Wiley Online Library